Biographical Memoirs: Volume 62 (1993)
Chapter: HARVARD AND THE CHILIDREN'S CANCER RESEARCH FOUNDATION, 1954-59
induced pituitary tumors in mice. Further investigation with Burnett and others led to the finding of a thyroid-pituitary axis whose manipulation could produce at will either thyroid or pituitary tumors.
HARVARD AND THE CHILIDREN'S CANCER RESEARCH FOUNDATION, 1954-59
Despite the productivity of these Oak Ridge years, Jacob yearned for a more academic atmosphere and in 1950 welcomed an invitation by Sidney Farber to join him as associate director and chairman of the experimental pathology section of the Children's Cancer Research Foundation in Boston, supported by the so-called Jimmy Fund, named after a young cancer victim cured by chemotherapy. These were also fruitful years of research, which Jacob modestly attributed "to the fame of Harvard, which . . . channeled to my laboratories guest investigators from . . . Australia, England, Israel, India, Japan, ... and the U.S.",2 and the unparalleled opportunity of collaborating with the many talented members of Harvard's faculty.
With Paul Hagen, the transplantable mastocytoma that Jacob had developed earlier was shown to produce heparin, serotonin, and histamine, a striking example of a transplantable tumor that retains considerable functional activity. Other notable Harvard faculty who contributed materially to Jacob's investigations of endocrine neoplasms were Jean Mayer on the obesity-inducing adrenotropic tumors, and Gregory Pincus and Eric Bloch on the steroids formed by these tumors. Several of the guest investigators—Donald Metcalf, now head of the Walter and Eliza Hall Institute of Melbourne, Australia; Nechama Haran-Ghera of the Weizmann Institute, Rehovot, Israel; Kelly Clifton, now at the University of Wisconsin; Gordon Sato, now at the W. Alton Jones Cell Science Center, Lake Placid; and Untae Kim of the
